Literature DB >> 34163555

Recurrent Miller Fisher: A Case Report Along With a Literature and an EMG/NCS Review.

Jonathan Morena1, Bakri Elsheikh1, J Chad Hoyle1.   

Abstract

MFS has been reported to recur in 10-12% of patients. There may be a genetic component related to HLA-DR2. Anti-GAD antibodies can be present in MFS along with anti-GQ1b. Common EMG/NCS associations consist of a predominantly axonal, sensory polyneuropathy and absent H reflexes. A 32-year-old female with a history of hypothyroidism presented to our institution twice with symptoms of diplopia, lower extremity weakness and distal paresthesias occurring a year apart. She had ophthalmoplegia, reduced reflexes, and ataxia on exam. CSF showed a borderline elevated protein of 47 and white blood cells <3. She was positive for anti-GQ1b both times. Her anti-GAD65 antibody was elevated during both admissions. EMG/NCS on her first admission revealed comparatively reduced sensory nerve action potentials (SNAPs) and a normal blink reflex. Her SNAPs improved on the second admission, however, the EMG was performed only 2 days after the onset of her symptoms, limiting some early findings that may have not matured electrophysiologically. She was treated with IVIG on both occasions with rapid recovery within 5 days. This case highlights the fact that MFS can be recurrent. It also provides further evidence that anti-GAD antibodies may be associated with MFS. Reported findings of the blink reflex in MFS are diverse and further data is needed to determine if certain findings are more predominant than others. Treatment typically consists of IVIG, though steroids may also be considered for recurrence. Prognosis is generally favorable, regardless of treatment.
© The Author(s) 2021.

Entities:  

Keywords:  Guillain barre syndrome; autoimmune disorders; miller fisher syndrome; neuromuscular disease; neurophysiology

Year:  2021        PMID: 34163555      PMCID: PMC8182394          DOI: 10.1177/1941874420987053

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN: 1941-8744


  15 in total

1.  Recurrent Miller Fisher syndrome: clinical and laboratory features and HLA antigens.

Authors:  K Chida; H Nomura; H Konno; S Takase; Y Itoyama
Journal:  J Neurol Sci       Date:  1999-06-01       Impact factor: 3.181

2.  An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia).

Authors:  M FISHER
Journal:  N Engl J Med       Date:  1956-07-12       Impact factor: 91.245

3.  Successful steroid treatment for recurrent Miller Fisher syndrome.

Authors:  Shuta Toru; Maya Ohara; Yumiko Hane; Taro Ishiguro; Takayoshi Kobayashi
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

4.  Neuropathy in the Miller Fisher syndrome: clinical and electrophysiologic findings.

Authors:  R D Fross; J R Daube
Journal:  Neurology       Date:  1987-09       Impact factor: 9.910

5.  Miller Fisher syndrome with positivity of anti-GAD antibodies.

Authors:  Vladimiro Pietrini; Giovanni Pavesi; Francesca Andreetta
Journal:  Clin Neurol Neurosurg       Date:  2012-12-17       Impact factor: 1.876

Review 6.  Electrophysiology in Fisher syndrome.

Authors:  Satoshi Kuwabara; Yukari Sekiguchi; Sonoko Misawa
Journal:  Clin Neurophysiol       Date:  2016-11-20       Impact factor: 3.708

7.  Relapsing ophthalmoparesis-sensory neuropathy syndrome.

Authors:  J G Kaplan; H H Schaumburg; A Sumner
Journal:  Neurology       Date:  1985-04       Impact factor: 9.910

8.  Serial neurophysiological and neurophysiological examinations for delayed facial nerve palsy in a patient with Fisher syndrome.

Authors:  Motoyuki Umekawa; Keiko Hatano; Hideyuki Matsumoto; Takahiro Shimizu; Hideji Hashida
Journal:  Rinsho Shinkeigaku       Date:  2017-04-27

9.  Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination.

Authors:  Y Nishimoto; M Odaka; K Hirata; N Yuki
Journal:  J Neuroimmunol       Date:  2004-03       Impact factor: 3.478

10.  Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy.

Authors:  Steve Vucic; Kevin D Cairns; Kristin R Black; Peter Siao Tick Chong; Didier Cros
Journal:  Clin Neurophysiol       Date:  2004-10       Impact factor: 3.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.